Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 15/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7192822 | 0.99 | CCR3 (0.58) | CCR3HTR2AOPRM1 | |
| SCHEMBL4771516 | 0.89 | TMEM97 (0.62) | CCR3 | |
| Hydrochloric Acid SCHEMBL6056725 | 0.88 | TMEM97 (0.61) | CCR3 | |
| Hydrochloric Acid SCHEMBL7193482 | 0.88 | TMEM97 (0.61) | CCR3 | |
| Hydrochloric Acid SCHEMBL6056689 | 0.86 | CCR3 (0.71) | CCR3HTR2A | |
| SCHEMBL4778089 | 0.85 | CCR3 (0.77) | CCR3HTR2A | |
| SCHEMBL4770891 | 0.85 | CCR3 (0.54) | CCR3HTR2A | |
| Hydrochloric Acid SCHEMBL4775114 | 0.84 | CCR3 (0.64) | CCR3HTR2A | |
| Hydrochloric Acid SCHEMBL7192828 | 0.84 | CCR3 (0.53) | CCR3HTR2A | |
| SCHEMBL4775648 | 0.82 | CCR3 (0.54) | CCR3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | CCR3 3/4885HTR2A 629/4885OPRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.